Biotherapy (Dordrecht, Netherlands)最新文献_第3页

The role of genetically-based metabolic polymorphisms in human cancer: an ecological study of bladder cancer and N-acetyltransferase in 23 populations. 基于遗传的代谢多态性在人类癌症中的作用:23个人群膀胱癌和n -乙酰转移酶的生态学研究。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1023/a:1007919220399

P Vineis, T Martone

引用次数: 3

Pesticide distribution and movement. 农药的分配和运输。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1023/a:1007961524517

J Notario del Pino, R Díaz Díaz

引用次数: 4

Yeast strains to detect genomic deletions induced by carcinogens in cell-cycle arrested cells. 在细胞周期阻滞细胞中检测由致癌物诱导的基因组缺失的酵母菌株。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1023/a:1007978011313

A Galli, R H Schiestl

引用次数: 1

Antigen-specific therapies in multiple sclerosis. 抗原特异性治疗多发性硬化症。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1007/BF02678302

J M van Noort

引用次数: 7

Nasal administration of arthritis-related T cell epitopes of heat shock protein 60 as a promising way for immunotherapy in chronic arthritis. 热休克蛋白60与关节炎相关的T细胞表位鼻腔给药是一种有前景的慢性关节炎免疫治疗方法。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1007/BF02678298

B Prakken, M Wauben, P van Kooten, S Anderton, R van der Zee, W Kuis, W van Eden

{"title":"Nasal administration of arthritis-related T cell epitopes of heat shock protein 60 as a promising way for immunotherapy in chronic arthritis.","authors":"B Prakken, M Wauben, P van Kooten, S Anderton, R van der Zee, W Kuis, W van Eden","doi":"10.1007/BF02678298","DOIUrl":"https://doi.org/10.1007/BF02678298","url":null,"abstract":"Adjuvant Arthritis (AA) can be induced in Lewis rats by immunisation with mycobacterial antigens. The disease can be passively transferred with T cell clone A2b, which recognises the 180-188 amino acid sequence in mycobacterial heat shock protein 60 (hsp60) and which crossreacts with crude cartilage proteoglycans. We succeeded to induce peripheral tolerance to this AA-associated T cell epitope following nasal administration of a peptide containing this epitope (mycobacterial hsp60 176-190). In rats treated nasally with 176-190 and immunised with mycobacterial hsp60, proliferative responses to 176-190 were reduced. AA was inhibited nasally with 176-190 treated rats and not in rats nasally treated with a control mycobacterial hsp60 peptide (211-225). Moreover, nasal 176-190 led to similar arthritis protective effects in a non-microbially induced experimental arthritis (avridine induced arthritis). In a subsequent study we tried to prevent and to treat AA through nasal administration of mycobacterial hsp60 peptide 180-188 and a peptide analogue of 180-188, 180-188(L183->A) (Alanine 183), which has been shown to have an increased MHC-binding affinity for rat RT1 Bl and an increased capacity to inhibit the proliferative A2b response in vitro. We found that nasal administration of 180-188 had a moderate arthritis suppressive effect in AA, whereas its analogue peptide Alanine 183, had a strong suppressive effect. This strong arthritis suppressive effect was only partly due to the higher MHC-binding affinity for rat RT1 Bl. Furthermore, it was possible to passively transfer nasal Alanine 183 induced disease protection. The present findings may in our view offer novel prospects for immunotherapy through nasal administration of (analogue) peptides, with a mimicry relationship with joint specific cartilage proteoglycan epitopes.","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"10 3","pages":"205-11"},"PeriodicalIF":0.0,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02678298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20481106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. 肝细胞癌患者血清硫氧还蛋白水平升高。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1023/a:1008032703468

K Miyazaki, N Noda, S Okada, Y Hagiwara, M Miyata, I Sakurabayashi, N Yamaguchi, T Sugimura, M Terada, H Wakasugi

{"title":"Elevated serum level of thioredoxin in patients with hepatocellular carcinoma.","authors":"K Miyazaki, N Noda, S Okada, Y Hagiwara, M Miyata, I Sakurabayashi, N Yamaguchi, T Sugimura, M Terada, H Wakasugi","doi":"10.1023/a:1008032703468","DOIUrl":"https://doi.org/10.1023/a:1008032703468","url":null,"abstract":"Thioredoxin (TRX) is known to contain an active site with a redox-active disulfide and has various biological activities. The objective of the present study was to investigate whether circulating TRX levels are elevated in patients with chronic hepatitis (CH) or liver cirrhosis (LC) and hepatocellular carcinoma (HCC). An anti-TRX monoclonal antibody and polyclonal antibodies that specifically recognize TRX, were generated and used for the development of an ELISA system to measure TRX levels in human serum. The geometric mean and its 95% confidence interval of serum level of TRX in healthy volunteers was 81.75 ng/ml (74.60-89.59 ng/ml). The serum level of TRX in LC/CH patients without HCC was 80.87 ng/ml (69.66-93.88 ng/ml). The value was not statistically different from that in serum from normal volunteers (p=0.69). In contrast, the serum level of TRX in patients with HCC was 147.35 ng/ml (125.53-172.96 ng/ml), which was significantly higher when compared with the level in serum of normal volunteers (p<0.001) and in serum of LC/CH patients without HCC (p<0.001). In four patients with HCC, the initially high level of serum TRX (>150 ng/ml) decreased below 150 ng/ml after surgical removal of the tumor. The data reported herein revealed that patients with HCC had a significantly elevated serum level of TRX, suggesting that measurement of serum of TRX might be a useful clinical parameter when HCC is suspected.","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"11 4","pages":"277-88"},"PeriodicalIF":0.0,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/a:1008032703468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20855796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 60

Oral administration of HSP-containing E. coli extract OM-89 has suppressive effects in autoimmunity. Regulation of autoimmune processes by modulating peripheral immunity towards hsp's? 口服含热休克蛋白的大肠杆菌提取物OM-89对自身免疫有抑制作用。通过调节对热休克蛋白的外周免疫调节自身免疫过程?

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1007/BF02678300

U Wendling, J C Farine

{"title":"Oral administration of HSP-containing E. coli extract OM-89 has suppressive effects in autoimmunity. Regulation of autoimmune processes by modulating peripheral immunity towards hsp's?","authors":"U Wendling, J C Farine","doi":"10.1007/BF02678300","DOIUrl":"https://doi.org/10.1007/BF02678300","url":null,"abstract":"OM-89 (Subreum) is an E. coli extract used for oral administration in the treatment of rheumatoid arthritis. It contains bacterial heat shock proteins, namely hsp60 and hsp70, which were shown to be major immunogenic constituents of the drug. Immunity to bacterial heat-shock antigens was shown to be a means of immunomodulation of (experimental) autoimmune disease and possibly inflammation in general. This was demonstrated for mycobacterial hsp60 respectively hsp70 in autoimmune disease models for arthritis, diabetes and encephalitis. Parallel to the effects displayed by immunisation with hsp, oral administration of hsp-containing OM-89 was found to modify autoimmune disease in a number of animal models, such as for arthritis, diabetes and SLE. In rats immunisation with OM-89 was found to lead to proliferative T cell responses to hsp60 and hsp70 of both E. coli and mycobacterial origin. Conversely, immunisation with hsp antigens could induce T cell reactivity specific for OM-89. Given this and the autoimmune disease modulating properties of both hsp and OM-89 it is argued that OM-89 acts via the same mechanism as proposed for hsp: that peripheral tolerance is induced at the level of regulatory T cells with specificity for heat-shock proteins. This may constitute one mode of action for OM-89 as an arthritis suppressive oral drug in man.","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"10 3","pages":"223-7"},"PeriodicalIF":0.0,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02678300","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20481083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

The use and interpretation of biomarkers of environmental genotoxicity in humans. 人类环境遗传毒性生物标志物的使用和解释。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1023/a:1007990300835

R J Albertini

引用次数: 20

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources. 细胞因子对不同人造血干细胞体外扩增的影响。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1007/BF02678549

S Eridani, U Mazza, P Massaro, M L La Targia, A T Maiolo, A Mosca

{"title":"Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources.","authors":"S Eridani, U Mazza, P Massaro, M L La Targia, A T Maiolo, A Mosca","doi":"10.1007/BF02678549","DOIUrl":"https://doi.org/10.1007/BF02678549","url":null,"abstract":"Human pluripotential stem cells (PSC) are currently the target for transplantation attempts and genetic manipulation. We have therefore investigated the frequency and the expansion potential of PSC's in different types of blood samples. CD 34+ cells were thus obtained from human bone marrow (BM), as well as from peripheral blood (PB) and cord blood (CB) samples. After immuno-magnetic separation the highest yields of CD 34+ cells were from BM (1.08-2.25%) and CB (0.42-1.32%) while PB samples gave much lower values. Suspension cultures of PSC's from the three sources were then set up, in the presence of combinations of haemopoietic growth factors. A remarkable amplification of the nucleated cell pool was observed reaching a maximum between 10 and 15 days of culture; earliest and maximum expansion (up to 220-fold) was achieved when Erythropoietin (Epo) was added to the culture medium, but this resulted in reduction of colony-forming cells and differentiation into erythroid progenitors. Clonogenic tests for BFU-E's derived colonies showed a peak value at 5 days of liquid culture. Further studies are advisable to establish the best cytokine combination for a valuable ex vivo expansion, coupled with preservation of stem cell properties.","PeriodicalId":77043,"journal":{"name":"Biotherapy (Dordrecht, Netherlands)","volume":"10 4","pages":"295-8"},"PeriodicalIF":0.0,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02678549","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20512427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

The making of an erythroid cell. Molecular control of hematopoiesis. 红体细胞的形成造血的分子控制。

Biotherapy (Dordrecht, Netherlands) Pub Date : 1998-01-01 DOI: 10.1007/BF02678546

A R Migliaccio, G Migliaccio

引用次数: 11